

## Reference

### G-5023

1. Veeranna V, Zalawadiya SK, Niraj A, et al. Homocysteine and reclassification of cardiovascular disease risk. *J Am Coll Cardiol*. Aug 30 2011; 58(10): 1025-33. PMID 21867837
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA*. Oct 2002; 288(16): 2015-22. PMID 12387654
3. Shoamanesh A, Preis SR, Beiser AS, et al. Circulating biomarkers and incident ischemic stroke in the Framingham Offspring Study. *Neurology*. Sep 20 2016; 87(12): 1206-11. PMID 27558379
4. Han L, Wu Q, Wang C, et al. Homocysteine, Ischemic Stroke, and Coronary Heart Disease in Hypertensive Patients: A Population-Based, Prospective Cohort Study. *Stroke*. Jul 2015; 46(7): 1777-86. PMID 26038522
5. Shi Z, Guan Y, Huo YR, et al. Elevated Total Homocysteine Levels in Acute Ischemic Stroke Are Associated With Long-Term Mortality. *Stroke*. Sep 2015; 46(9): 2419-25. PMID 26199315
6. Wang C, Han L, Wu Q, et al. Association between homocysteine and incidence of ischemic stroke in subjects with essential hypertension: a matched case-control study. *Clin Exp Hypertens*. 2015; 37(7): 557-62. PMID 25992490
7. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. *Am J Cardiol*. May 01 2010; 105(9): 1284-8. PMID 20403480
8. Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev*. Aug 17 2017; 8(8): CD006612. PMID 28816346
9. Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev*. Jan 31 2013; (1): CD006612. PMID 23440809
10. Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev*. Jan 15 2015; 1: CD006612. PMID 25590290
11. Park JH, Saposnik G, Ovbiagele B, et al. Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis. *Int J Stroke*. Feb 2016; 11(2): 206-11. PMID 26783312
12. Yi X, Zhou Y, Jiang D, et al. Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery

- disease: A meta-analysis of randomized controlled trials. *Exp Ther Med*. May 2014; 7(5): 1100-1110. PMID 24940394
13. Liu Y, Tian T, Zhang H, et al. The effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease: a meta-analysis of randomized controlled trials. *Atherosclerosis*. Jul 2014; 235(1): 31-5. PMID 24814647
  14. Huang T, Chen Y, Yang B, et al. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. *Clin Nutr*. Aug 2012; 31(4): 448-54. PMID 22652362
  15. Zhou YH, Tang JY, Wu MJ, et al. Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. *PLoS One*. 2011; 6(9): e25142. PMID 21980387
  16. Clarke R, Halsey J, Bennett D, et al. Homocysteine and vascular disease: review of published results of the homocysteine-lowering trials. *J Inherit Metab Dis*. Feb 2011; 34(1): 83-91. PMID 21069462
  17. van Dijk SC, Enneman AW, Swart KM, et al. Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial. *J Hypertens*. Sep 2015; 33(9): 1897-906; discussion 1906. PMID 26147383
  18. Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. *JAMA*. Jun 23 2010; 303(24): 2486-94. PMID 20571015
  19. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med*. Apr 13 2006; 354(15): 1567-77. PMID 16531613
  20. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med*. Apr 13 2006; 354(15): 1578-88. PMID 16531614
  21. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med*. May 13 1999; 340(19): 1449-54. PMID 10320382
  22. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost*. Feb 2005; 3(2): 292-9. PMID 15670035
  23. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. *Arch Intern Med*. Oct 26 1998; 158(19): 2101-6. PMID 9801176
  24. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost*. Dec 1998; 80(6): 874-7. PMID 9869152

25. Naess IA, Christiansen SC, Romundstad PR, et al. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population--results from the HUNT 2 study. *Br J Haematol*. May 2008; 141(4): 529-35. PMID 18318759
26. Zhou K, Zhao R, Geng Z, et al. Association between B-group vitamins and venous thrombosis: systematic review and meta-analysis of epidemiological studies. *J Thromb Thrombolysis*. Nov 2012; 34(4): 459-67. PMID 22743781
27. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. *Blood*. Jan 01 2007; 109(1): 139-44. PMID 16960155
28. Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. *Ann Intern Med*. Jun 05 2007; 146(11): 761-7. PMID 17470822
29. National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification [CG181]. Updated September 2016; <https://www.nice.org.uk/guidance/cg181/chapter/1-Recommendations#identifying-and-assessing-cardiovascular-disease-cvd-risk-2>. Accessed November 1, 2022.
30. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. Dec 2014; 45(12): 3754-832. PMID 25355838
31. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke*. Jul 2021; 52(7): e364-e467. PMID 34024117
32. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Sep 10 2019; 140(11): e596-e646. PMID 30879355
33. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Mar 21 2017; 135(12): e726-e779. PMID 27840333
34. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of

- Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Jul 01 2014; 63(25 Pt B): 2935-2959. PMID 24239921
35. Myers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. *Clin Chem*. Feb 2009; 55(2): 378-84. PMID 19106185
  36. Maynard G. Preventing hospital-associated venous thromboembolism: a guide for effective quality improvement. 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
  37. National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospita-acquired deep vein thrombosis or pulmonary embolism. [NG89]. 2018; <https://www.nice.org.uk/guidance/ng89>. Accessed October 31, 2022.
  38. U.S. Preventive Services Task Force. Cardiovascular Disease: Risk Assessment Using Nontraditional Risk Factors. 2018; <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cardiovascular-disease-screening-using-nontraditional-risk-assessment>. Accessed October 14, 2022.